A luglio 1987, ha conseguito la specializzazione in ONCOLOGIA MEDICA.

Transcript

1 CURRICULUM VITAE INFORMAZIONI PERSONALI Nome Mariarosa Coccaro Data di nascita 28/03/1959 Qualifica Amministrazione Incarico attuale Dirigente Medico IRCCS CROB Via Padre Pio, Rionero in Vulture (PZ) Staff Oncologia Medica Numero telefonico dell ufficio fax Cellulare istituzionale mcoccaro@hotmail.com TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE Titolo di studio Altri titoli di studio e professionali Esperienze professionali (incarichi ricoperti) 1984:Laurea in Medicina e Chirurgia conseguita presso l Università degli Studi di Napoli voto 107/ : Specializzazione in Oncologia Medica presso l'università degli studi di Napoli, voto 67/ : Specializzazione in Ematologia, presso l'università La Sapienza di Roma - Da maggio 1984 a giugno 1985, ha svolto attività di medico volontario presso l Ospedale San Leonardo (SA), reparto di medicina Generale. Da luglio 1985 a settembre 1989, ha lavorato come medico volontario, presso il Reparto di Oncologia Medica dell Ospedale Cardarelli (NA). A luglio 1987, ha conseguito la specializzazione in ONCOLOGIA MEDICA. nel 1988 ha svolto servizio di guardia medica presso ex U.S.L 60 regione Campania. Nel 1989 ha svolto servizio di guardia medica ex U.S.l 55 della regione Campania. Da settembre 1989 a maggio 1998, ha lavorato presso l Ospedale di Eboli come Dirigernte Medico I livello area medica, reparto Geriatria, 1

2 referente del modulo di oncologia geriatria. Da settembre 1990 a marzo 1991, ha frequentato la Columbia University di New-York, reparto di onco-ematologia. A novembre 1991, ha conseguito la specializzazione in Ematologia clinic, presso l Università La Sapienza di Roma. Nel 1995, ha superato U.S.M.L.E. Da giugno 1998 a tutt oggi lavora Presso l Unità Operativa di Oncologia Medica del C.R.O.B-IRCCS di Rionero in Vulture, come dirigente medico ex I livello. Dal febbraio 2006 a luglio 2008, per alcuni mesi ha svolto Funzioni di direttore dell Unità operativa. Capacità linguistiche Capacità nell uso delle tecnologie Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare) Ha partecipato a sperimentazioni cliniche e tutt ora è responsabile di alcuni protocolli della unità operativa. Inglese fluente. Ottima capacità nell'uso dei sistemi operativi Windows ed Apple ELENCO PUBBLICAZIONI IN ORDINE CRONOLOGICO 1)- Il CEA-test nella diagnostica oncologica (Edizioni il Cardarelli, 1984). 2) L epatopatia alcolica (contributo clinico-statistico) pubblicato su Rassegna italiana di scienze N.3 MAGGIO Sindrome paraneoplastica da ipernefroma, ( ANTOLOGIA MEDICA ITALIANA, VOL.V, 1985). 3) Attività senologica del servizio di Oncologia di Salerno nel quinquennio (Rivista di Oncologia, luglio-dicembre 1987). 4) Metastasi ossee da osteosarcoma (SIPDTT VOL. II). Inibizione dell attività biologica della prostaciclina nei pazienti affetti da tumori maligni dell osso (SIPDTT VOL. II). 5) Treatment of advanced head and neck cancer with the chemoterapy (160 International congress of chemoterapy, abstracts Jerusalem 1989 pag. 48). Infusione continua protatta di 5 fluorouracile nel trattamento delle neoplasie 2

3 del colon-retto in fase avanzata (Tumori, vol. 75n. 4, supplemento n. 4, pag. 21). 6) Chemioterapia adiuvante settimanale con 5 fluorouracile ed acido folinico sull anziano affetto da adenocarcinoma del colon-retto Minerva italica luglioagosto 1999 pag ) Oxaliplatin ( L-OHP) combined with continous infusion 5-Fluorouracil (5FU) and folinic acid based regimen in advanced colorectal cancer patients. confirmatory data on efficacy and toxicity, Annals of Oncology,Vol 11, Suppl. 2 pag. 64, ) Weekly adjuvant chemotherapy containing 5-Fluorouraciland Folinic Acid in radically resected colon-rectal patients: toxicity and preliminary results.abstract 4 th International Conference on Biology,Prevention and Treatment of Gastrointestinal Malignancies,Cologne, Germany, September,6-8, 2001, pag ) Oxaliplatin, Folinic Acid and Fluorouracil Is An Active Combination with Acceptable Toxicity In Advanced Colorectal Cancer.Abstract 4 th International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignicies. Cologne,Germany, September 6-8, 2001, pag.121. Long term infusional systems: complications in cancer patients. Tumori Sep-Oct; 87(5): ) Pumonary blastoma after liver transplant: a case report.tumori.2002 Mar-Apr; 88(2): CD expression in B cell chronic lymphocitic leukaemia. The Hematology Journal Vol.3 Supplement 1-June 2002,page ) Primary central nervous system lymphoma (PCNSL): analisys of 14 patients. The Hematology Journal. Vol. 3, Supplement 1 ; June Page ) A modified FND( fludarabine, mitoxantrone and dexamethazone) regimen in previously untreated follicular non Hodgkin lymphoma. The haematology Journal. Vol. 3 supplement 1 June 2002, page ) Phase II study with vinorelbine and continuous infusion of 5- Fluorouracilin pretraeted metastatic breast cancer patients: preliminary data. Annals of Oncology, suppl. 3,Oct 2002.page ) Chemotherapy in advanced bilio-pancreatic cancer. A monoistitutional observation.annalsof Oncology, suppl. 3,Oct 2002, page ) Dose-finding weekly Docetaxel plus estramustine in patients with 3

4 hormorefractory metastatic prostate cancer: preliminary results. Annals of Oncology, Suppl. 3, Oct 2002, page ) Sequential evaluation of CD38 expression in B-cell chronic lymphocitic leukaemia Abstracts book. Crhonic limphocitic leukaemia Congress, Oct 10 th - 11 th, 2002,Bologna Italy. - Management of advanced bilio-pancreatic cancer. A monoistitutional observation. Annals of Oncology, suppl. 5, Oct 2002, page ) "Should we continue to study high-dose chemotherapy in metastatic breast cancer? A critical review of the published data". Bone Marrow transplant Apr;31(7): ) "Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of Rituximab".Leuk Lymphoma Mar-Apr; 88(2): ) Cisplatin and weekly Docetaxel in patients with advanced non-small lung carcinoma. Phase II study. Annals of Oncology, 2003 suppl 4,vol 14, iv20. 20) Primary non Hodgkin lymphoma of the breast: a report of 7 cases. Annals of Oncology, 2003, suppl 4. vol 14, iv ) Primary central nervous system lymphoma in immunocompetent adults: analysis of a retrospective series of patients treated with idarubicin-containing regimen and radiotherapy. Haematologica, 2003, Vol 88, suppl. n. 15, ) A case of B cell chronic lymphocytic leucemia with osteolytic bone lesions. Haematologica, vol. 88, suppl 15, ) Quantitative evaluation of CD33 (expression in B-cell chronic lymphocitic leucemia. European journal of Histochemistry, vol 47, suppl 2, ) Incidence and differential diagnosis with others neoplasms of lymphonodes sarcoidosis: our experience. Annals of Oncology: 2004, suppl 2, pag. ii 79, abst 4

5 G ) Acute myeloid leukaemia M5A with co-expression of NK and lymphoid antigens in blast cells and complex karotype: a case report. Annals of Oncology: 2004, suppl 2, pag. ii80, abst G12. 26) Radiation therapy and temozolomide as adjuvant therapy in patients with glioblastoma: preliminary data. Annals of Oncology: 2004, suppl 2, pag. ii 86, abs H19. 27) Dose-finding weekly Docetaxel plus Estramustine in patients with Hormoresistant metastatic prostate cancer. Annals of Oncology: 2004, suppl 2, pag.ii96, abs L24. 28) Management of high-dose Melphalan-induced oral mucositis: our experience. Annals of Oncology: 2004, suppl 2, pag. ii 112, abs N47. 29) The impact of implanted venous systems on normal daily activities in cancer patients. Annals of Oncology: 2004, suppl 2, pag ii112, abs N48. 30) Ruolo della chemioterapia ad alte dosi nel trattamento del carcinoma della mammella: review della letteratura. Oncologia ed Ematologia anno 6 n. 4, ) High-dose of Epoietin Alfa in patients with low-risk Myelodisplastic Syndromes (MDS): A single Institution experience. Blood vol. 103, n.12, 2004, abs ) Our experience with cisplatin+weekly docetaxel in patients with advanced non-small lung cancer. Annals of Oncology, vol. 15, suppl 3, 2004, abs 680P. 33) Linezolid-induced bradycardia: a case report. International Journal of Antimicrobial Agents 23 (2004) ) Primary Chemo-radiation Treatment in rectal cancer. Preliminary results of a monoistitutional Experience 16 TH International congress on Anti-Cancer treatment. February

6 35) Cisplatin and weekly docetaxel as first-line in patients with advanced nonsmall cell lung carcinoma:a phase II study, TUMORI vol. 91, n. 2 pag , ) Dose-finding study of weekly docetaxel plus estramustine in patints with hormono-refractory metastatic prostate cancer. TUMORI, vol. 91, n. 4, pag , ) cardiotoxicity and 5-fluorouracil continuous infusion: a monoistitutional experience Annals of Oncology, abs c32, vii37, suppl. 7, ) importance of 5-FU infusion duration and toxicity during CMF administration in adijvant setting Annals of Oncology, abs A1, suppl 7, ) Xeloda and eloxatin as firrst line chemotherapy for advanced colorectal cancer patients. Preliminary data about activity and toxicity of a monoistitutional experience. Annals of Oncology, abs D17, suppl. 7, ) Nutritional support with total parenteral support in cancer patients with high dose chemotherapy folowed by peripheral blood progenitor cells (PBPCs) transplantion: our experience. Annals of Oncology, abs H 15, suppl 7, ) Electrocardiographic abnormalities and scintigraphic perfusion defects following combined chemotherapy and left thoracic: 2 cases. 17 th ICAT ) 5 fluorouracil cardiotoxicity is more frequent in patients with risk factors for coronary artery disease or with a previous myocardial infarction: a possible synergism between vasospastic and throogenic mechanisms in determining cardiotoxicity. Annals of Oncology suppll. 7 june ) Stes-Johnson syndrome to valacicloviri a patient with non Hodgkinlymphoma Annals of Oncology, supp. 9, abs n.698,page ix ) Our experience with transdermal therapeutic system fentanyl in the pain management of high dose chemotherapy associated oral mucositis. Annals of 6

7 Oncology abs, suppl 9, 2006, abs n. 1037P.pag. ix299 44) 5FU infusion duration and toxicity during CMF administration in adjuvant setting of breast cancer. Annals of Oncology, suppl 9, 2006, abs 303, pag. i ) Enhanced cardiotoxicity in breast cancert patients treated with combinewd chemoteraphy and left thoracic radiotherapy: myocardial perfusion abnormalities and heart failure Annals of Oncology, suppl 9, 2006, abs n. 317, pag. Ix ) Myocardal perfusion detects after radiation therapy and Antracycline chemotherapy for left breast cancer: a possible marker of mocrovascolar damage. Three cases and review of the literarature. Tumori, vol. 94,. 1page , ) Late cardiac effects of radiotherapy and chemotherapy in early breast cancer. JCO 3288; ) The clinical impact of cardiologic follow-up in breast cancer survivors: an observational study Int J of immunophatology and pharmacology vol 23, n. 4, , ) Contractile reserve as a marker of preclinical cardiotoxity, JCO vol. 28 n. 36 pag. E769, ) Anal metastasis from breast cancer:a case report and review of the literature: Future Oncology vol 8(3), pag. 1-4, 2012 Li 25/07/2012 Dr Mariarosa Coccaro 7

8 8